These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 11032609)

  • 1. Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson's disease.
    Clarke CE; Davies P
    J Neurol Neurosurg Psychiatry; 2000 Nov; 69(5):590-4. PubMed ID: 11032609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute challenge with apomorphine and levodopa in Parkinsonism.
    Rossi P; Colosimo C; Moro E; Tonali P; Albanese A
    Eur Neurol; 2000; 43(2):95-101. PubMed ID: 10686467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis.
    Merello M; Nouzeilles MI; Arce GP; Leiguarda R
    Mov Disord; 2002 Jul; 17(4):795-8. PubMed ID: 12210878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apomorphine test in de novo Parkinson's disease.
    Bonuccelli U; Piccini P; Del Dotto P; Pavese N; D'Antonio P; Muratorio A
    Funct Neurol; 1992; 7(4):295-8. PubMed ID: 1427361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
    Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenge tests to predict the dopaminergic response in untreated Parkinson's disease.
    Hughes AJ; Lees AJ; Stern GM
    Neurology; 1991 Nov; 41(11):1723-5. PubMed ID: 1944899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The apomorphine test in parkinsonian syndromes.
    D'Costa DF; Abbott RJ; Pye IF; Millac PA
    J Neurol Neurosurg Psychiatry; 1991 Oct; 54(10):870-2. PubMed ID: 1744640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes.
    Hughes AJ; Lees AJ; Stern GM
    Lancet; 1990 Jul; 336(8706):32-4. PubMed ID: 1973218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apomorphine test for dopaminergic responsiveness: a dose assessment study.
    Bonuccelli U; Piccini P; Del Dotto P; Rossi G; Corsini GU; Muratorio A
    Mov Disord; 1993 Apr; 8(2):158-64. PubMed ID: 8474482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease.
    Albanese A; Bonuccelli U; Brefel C; Chaudhuri KR; Colosimo C; Eichhorn T; Melamed E; Pollak P; Van Laar T; Zappia M
    Mov Disord; 2001 Mar; 16(2):197-201. PubMed ID: 11295770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The apomorphine test for diagnosis of parkinsonian syndrome].
    Piccini P; Del Dotto P; Napolitano A; Pardini C; Bonuccelli U
    Riv Neurol; 1990; 60(6):221-3. PubMed ID: 2100046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apomorphine test for dopaminergic responsiveness in patients with previously untreated Parkinson's disease.
    Gasser T; Schwarz J; Arnold G; Trenkwalder C; Oertel WH
    Arch Neurol; 1992 Nov; 49(11):1131-4. PubMed ID: 1444878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease.
    Happe S; Tings T; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C
    Mov Disord; 2004 Dec; 19(12):1511-5. PubMed ID: 15390061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.
    Olanow CW; Factor SA; Espay AJ; Hauser RA; Shill HA; Isaacson S; Pahwa R; Leinonen M; Bhargava P; Sciarappa K; Navia B; Blum D;
    Lancet Neurol; 2020 Feb; 19(2):135-144. PubMed ID: 31818699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apomorphine for motor fluctuations and freezing in Parkinson's disease.
    Corboy DL; Wagner ML; Sage JI
    Ann Pharmacother; 1995 Mar; 29(3):282-8. PubMed ID: 7606075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IBZM-SPECT as predictor for dopamimetic responsiveness of patients with de novo parkinsonian syndrome.
    Oertel WH; Schwarz J; Tatsch K; Arnold G; Gasser T; Kirsch CM
    Adv Neurol; 1993; 60():519-24. PubMed ID: 8420182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease.
    Merello M; Lees AJ
    J Neurol Neurosurg Psychiatry; 1992 Nov; 55(11):1024-6. PubMed ID: 1469397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apomorphine in patients with Parkinson's disease.
    Muguet D; Broussolle E; Chazot G
    Biomed Pharmacother; 1995; 49(4):197-209. PubMed ID: 7669939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in the motor response to apomorphine between untreated and fluctuating patients with Parkinson's disease.
    Grandas F; Gancher ST; Rodriguez M; Lera G; Nutt JG; Obeso JA
    Clin Neuropharmacol; 1992 Feb; 15(1):13-8. PubMed ID: 1576595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.